articleTop 1% cited

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology · 2015 · Vol. 16(4) · pp. 375–384

Jeffrey S. Weber✉(Moffitt Cancer Center)Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center)David R. Minor(Northern California Melanoma Center)F. Stephen Hodi(Dana-Farber Cancer Institute)Ralf Gutzmer(Medizinische Hochschule Hannover)Bart Neyns(Universitair Ziekenhuis Brussel)Christoph Höeller(Medical University of Vienna)Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center)Wilson H. Miller(McGill University)Christopher D. Lao(University of Michigan–Ann Arbor)Gerald P. Linette(Washington University in St. Louis)L. Thomas(Hôpital Lyon Sud)Paul Lorigan(The Christie Hospital)Kenneth F. Grossmann(Huntsman Cancer Institute)Jessica C. Hassel(German Cancer Research Center)Michele Maio(University of Siena)Mario Sznol(Yale Cancer Center)Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")Peter Mohr(Elbe Kliniken Stade-Buxtehude)Bartosz Chmielowski(University of California, Los Angeles)Alan H. Bryce(Mayo Clinic in Arizona)Inge Marie Svane(Herlev Hospital)Jean‐Jacques Grob(Aix-Marseille Université)Angela M. Krackhardt(Technical University of Munich)Christine E. Horak(Bristol-Myers Squibb (United States))Alexandre Lambert(Bristol-Myers Squibb (Belgium))Arvin Yang(Bristol-Myers Squibb (United States))James Larkin(Royal Marsden Hospital)

View via DOI Publisher page

Cancer Immunotherapy and Biomarkers CAR-T cell therapy research Immunotherapy and Immune ResponsesOpen labelMedicineNivolumabOncologyChemotherapyInternal medicineIpilimumabRandomized controlled trialImmunotherapyCancer

MeSH terms

CarboplatinIpilimumabNivolumabAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMelanomaMiddle AgedNeoplasm StagingPaclitaxel

Funding

GlaxoSmithKline
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
National Institute for Health and Care Research
National Institutes of Health

Citations

2,648

FWCI

167.40

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma